Preventative effects of anastrozole in post-menopausal women who are at high-ris...
Prof Jack Cuzick - Queen Mary University of London, London, UK
Preventative effects of anastrozole in post-menopausal women who are at high-risk for developing breast cancer ( Prof Jack Cuzick - Queen Mary University of London, London, UK )
18 Dec 2019
How effective is accelerated partial breast irradiation in patients with early b...
Dr Icro Meattini - Univerity of Florence, Florence, Italy
How effective is accelerated partial breast irradiation in patients with early breast cancer? ( Dr Icro Meattini - Univerity of Florence, Florence, Italy )
18 Dec 2019
Predicting disease recurrence in patients with early triple-negative breast canc...
Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indi...
Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
18 Dec 2019
The emerging role of immunotherapy for the treatment of early and advanced breas...
Dr Rita Nanda - UChicago Medicine, Chicago, USA
The emerging role of immunotherapy for the treatment of early and advanced breast cancer ( Dr Rita Nanda - UChicago Medicine, Chicago, USA )
18 Dec 2019
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with op...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )
18 Dec 2019
Breast cancer incidence in post-menopausal women: Long-term influence of oestrog...
Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA
Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progestin versus oestrogen alone ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )
18 Dec 2019
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )
18 Dec 2019
Addition of S-1 to post-operative endocrine therapy for patients with hormone re...
Prof Masakazu Toi - Kyoto University, Kyoto, Japan
Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )
18 Dec 2019
Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-p...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )
18 Dec 2019
Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer p...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )
18 Dec 2019
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
18 Dec 2019
Challenges of treating elderly breast cancer patients
Dr Richard Simcock - Sussex Cancer Centre, Brighton, UK
Challenges of treating elderly breast cancer patients ( Dr Richard Simcock - Sussex Cancer Centre, Brighton, UK )
29 Nov 2019